In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 51-55

  Klugman, K P ^a   Gootz, T D ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMAFLOXACIN; TROVAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENE; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CULTURE MEDIUM; CZECH REPUBLIC; DRUG EFFICACY; ENZYME SUBUNIT; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PENICILLIN RESISTANCE; PH; PNEUMONIA; RABBIT; SLOVAKIA; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS DRUG ADMINISTRATION; SWEDEN; UNITED KINGDOM; UNITED STATES;

ANIMALS; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HYDROGEN-ION CONCENTRATION; MENINGITIS, PNEUMOCOCCAL; MICE; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; PENICILLIN RESISTANCE; PNEUMONIA, PNEUMOCOCCAL; RABBITS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030820653     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.51     Document Type: Article

References (23)

1. Perez-Trallero, E., Garcia-Arenzana, J. M., Jimenez, J. A. & Peris, A. (1990). Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 9, 905-6.
2. Lee, B. L., Padulay, A. M., Kimbrough, R. C., Jones, S. R., Chaisson, R. E. E., Mills, J. et al. (1991). Infectious complications with respiratory pathogens despite ciprofloxacin therapy. New England Journal of Medicine 325, 520-1.
3. Trautmann, M., Ruhnke, M., Borner, K., Wagner, J. & Koeppe, P. (1996). Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Antimicrobial Agents and Chemotherapy 40, 776-9.
4. Bradley, J. S. & Connor, J. D. (1991). Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Paediatric Infectious Disease Journal 10, 871-3.
5. John, C. C. (1994). Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clinical Infectious Diseases 18, 188-93.
6. Klugman, K. P. (1994). Pneumococcal resistance to the third-generation cephalosporins: clinical, laboratory and molecular aspects. International Journal of Antimicrobial Agents 4, 63-7.
7. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
8. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
9. Neu, H. C. & Chin, N.-X. (1994). In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-2622.
10. Child, J., Andrews, J., Boswell, F., Brenwald, N. & Wise, R. (1995). The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy 35, 869-76.
11. Thomson, K. S., Chartrand, S. A., Sanders, C. C. & Black, S. L. (1997). Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 41, 478-80.
12. Fuchs, P. C., Barry, A. L. & Brown, S. D. (1996). Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagnostic Microbiology and Infectious Diseases, in press.
13. Olsson-Liljequist, B., Hoffman, B. M. & Hedlund, J. (1994). Activity of CP-99,219 against blood isolates of Streptococcus pneumoniae in Sweden. In Program and Abstracts of the Thirty-fourth Interscience Conference of Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract F14. American Society for Microbiology, Washington, DC.
14. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Activity of CP-99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy 35, 230-2.
15. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1996). Activity of CP-99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. Journal of Antimicrobial Chemotherapy 37, 77-84.
16. Gootz, T. D., Brighty, K. E., Andersen, M. R., Schmieder, B. J., Haskell, S. L., Sutcliffe, J. A. et al. (1994). In-vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 19, 235-43.
17. Jones, R. N. (1994). Preliminary interpretive criteria for in vitro susceptibility testing of CP-99,219 by dilution and disk diffusion methods. Diagnostic Microbiology and Infectious Disease 20, 167-70.
18. Gootz, T. D., Zaniewski, R., Haskell, S., Schmieder, B., Tankovic, J., Girard, D. et al. (1996). Activity of the new fluoroquinolone (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrobial Agents and Chemotherapy, 40, 2691-7.
19. Girard, A. E., Girard, D., Gootz, T. D., Faiella, J. A. & Cimochowski, C. R. (1995). In-vivo efficacy of trovafoxacin (CP-99,219), a new quinolone with extended activities against Gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrobial Agents and Chemotherapy 39, 2210-6.
20. Azoulay-Dupuis, E., Bedos, J. P., Bauchet, J., Reux, V., Muffat-Joly, M. & Carbon, C. (1996). Efficacy of trovafloxacin against penicillin-susceptible and resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. In Program and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract B43. American Society for Microbiology, Washington, DC.
21. Nau, R., Schmidt, T., Kaye, K., Froula, J. L. & Tauber, M. G. (1995). Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrobial Agents and Chemotherapy 39, 593-7.
22. Klugman, K. P. & Wasas, A. (1995). In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 36, 873-4.
23. Urbaskova, P., Trupl, J., Hupkova, H., Appelbaum, P. C. & Jacobs, M. R. (1996). In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia. European Journal of Clinical Microbiology and Infectious Diseases 15, 686-8.